PHAT מכפיל EV/EBITDA Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals (PHAT) relies on stable demand within the gastroenterology niche, yet faces pressure from insurance companies and challenges in launching new drugs. The EV/EBITDA level over the time interval helps identify a local bottom, with the current status equal to 0.00. The business is shielded from trade conflicts and geopolitics, focusing on the US domestic market.

This indicator compares the total business value, including net debt, with operating profit before depreciation and amortization, allowing for an assessment of the asset's real value regardless of the tax burden. An analysis of the Enterprise Value to EBITDA ratio for Phathom Pharmaceuticals (PHAT) confirms capitalization resilience amid stringent FDA requirements and the protection of its market niche through exclusive patents, verifying the long-term strength of the company's position.